Pharmacological demonstration of the additive effects of angiotensin- converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects

Clinical and Experimental Hypertension

Volumn 19, Issue 5-6, 1997, Pages 937-951

  Azizi, M ^a   Guyene, T T ^a   Chatellier, G ^a   Menard J ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II antagonists and inhibitors ; Blood pressure drug effect ; Drug synergism

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CAPTOPRIL; ENALAPRIL; LOSARTAN; RENIN;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM DEPLETION;

EID: 0030744964     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969709083197     Document Type: Conference Paper

References (25)

1. Lees, K.R. The dose-response relationship with angiotensin converting enzyme inhibitors: effects on blood pressure and biochemical parameters. J Hypertens. 1992; 10 (suppl 5):S3-S11.
2. Meredith, P.A., Donnelly, R., Elliott, H.L., Howie, C.A., Reid, J.L. Prediction of the antihypertensive response to enalapril. J Hypertens. 1990; 8:1085-1090.
3. Juillerat, L., Nussberger, J., Ménard, J., Mooser, V., Christen, Y., Waeber, B., Graf, P., Brunner, H.R. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990; 16:564-572.
4. Van Den Meiracker, A.H., Man in't veld, A.J., Admiraal, P.J.J., Ritsema Van Eck, H.J., Boomsma, F., Derkx, F.H.M., Schalekamp, M.A.D.H. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment : does it exist and does it affect the antihypertensive response ? J Hypertens. 1992; 10:803-812.
5. Urata, H., Healy, B., Stewart, R.W., Bumpus, F.M., Husain, A. Angiotensin II forming pathways in normal and failing human hearts. Circ Res. 1990; 66:883-890.
6. Azizi, M., Chatellier, G., Guyene, T.T., Murieta-Geoffroy, D., Ménard, J. Additive effects of combined angiotensin converting enzyme inhibition and angiotensin n antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995; 92:825-834.
7. Azizi, M., Guyene, T.T., Chatellier, G., Wargon, M., Ménard, J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension. 1996:(In press).
8. Weisser, K., Schloos, J., Lehmann, K., Dusing, R., Vetter, H., Mutschler, E. Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. Eur J Clin Pharmacol. 1991; 40:95-99.
9. Ohtawa, M., Takayama, F., Saitoh, K., Yoshinaga, T., Nakashima, M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin n receptor antagonist, in humans. Br J Clin Pharmacol. 1993; 35:290-297.
10. Ménard, J., Boger, R.S., Moyse, D.M., Guyene, T.T., Glasmann, H.N., Kleinert, H.D. Dose-dependent effects of the renin inhibitor, zankiren HCL, after a single oral dose in mildly sodium depleted normotensive volunteers. Circulation. 1995; 91:330-338.
11. McGregor, G.A., Markandu, N.D., Smith, S.J., Sagnella, G.A., Morton, JJ. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature. 1981; 291:329-331.
12. Toffelmire, E.B., Slater, K., Corvol, P., Ménard, J., Schambelan, M. Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal subjects. Studies using a direct immunoradiometric assay. J Clin Invest. 1989; 83:679-687.
13. Cirollo, V.J., Gomez, H.J., Salonen, J., Salonen, R., Rissanen, V., Bolognese, J.A., Nyberg, R., Kristianson, K. Lisinopril: dose-peak effect relationship in essential hypertension. Br J Clin Pharmacol. 1988; 25:533-538.
14. Gradman, A.H., Arcuri, K.E., Goldberg, A.I., Ikeda, L.S., Nelson, E.B., Snavely, D.B., Sweet, C.S. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995; 25:1345-1350.
15. Guyene, T.T., Bellet, M., Sassano, P., Serrurier, D., Corvol, P., Ménard, J. Cross-over design for the dose determination of an angiotensin converting-enzyme inhibitor in hypertension. J Hypertens. 1989; 7:1005-1012.
16. Doig, J.K., MacFadyen, R.J., Sweet, C.S., Lees, K.R., Reid, J.L. Dose-ranging study of the angiotensin type I receptor antagonist Losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol. 1993; 21:732-738.
17. Quinn, S.J., Williams, G.H. Regulation of aldosterone secretion. Ann Rev Physiol. 1988; 50:409-426.
18. Byyny, R.L., Merrill, D.M., Bradstreet T.E., Sweet, C.S. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension. Cardiovasc Drug Therap. 1996: (In press).
19. Sadoshima, J.U., Xu, Y., Slayter, H.S., Izumo, S. Autocrine release of angiotensin II mediates strech-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993; 75:977-984.
20. Fernandez, L.A., Caride, V.J., Strömberg, C., Nävery, L., Wicke, J.D. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol. 1994; 24:937-940.
21. Stoll, M., Steckelings, U.M., Paul, M., Bottari, S.P., Metzger, R., Unger, T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995; 95:651-657.
22. Nakajima, M., Hutchinson, H.G., Fujinaga, M., Hayashida, W., Morishita, R., Zhang, L., Horiuchi, M., Pratt, R.E., Dzau, V.S. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the ATI receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA. 1995; 92:10663-10667.
23. Kerins, D.M., Hao, Q., Vaughan, D.E. Angiotensin induction of PAI-1 expression in endothelial cells in mediated by the hexapeptide angiotensin IV. J Clin Invest. 1995; 96:2515-2520.
24. Levy, B.I., Benessiano, J., Henrion, D., Caputo, L., Heymes, C., Duriez, M., Poitevin, P., Samuel, J.L. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest. 1996; 98:418-425.
25. Costerousse, O., Allegrini, J., Clozel, J.P., Ménard, J., Alhenc-Gelas, F. Increased angiotensin-converting enzyme (ACE) gene expression during inhibitor treatment. Comparison with other blockers of the renin-angiotensin system. J Hypertens. 1994; 12(Suppl 3):S126.